Panitumumab use in metastatic colorectal cancer and patterns of KRAS testing: Results from a Europe-wide physician survey and medical records review

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Trojan, Jörg ^a   Mineur, Laurent ^b   Tomášek, Jiří ^c   Rouleau, Etienne ^d   Fabian, Pavel ^c   De Maglio, Giovanna ^e   García Alfonso, Pilar ^f   Aprile, Giuseppe ^e   Taylor, Aliki ^g   Kafatos, George ^g   Downey, Gerald ^g   Terwey, Jan Henrik ^h   Van Krieken, J Han ⁱ  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b INSTITUT SAINTE CATHERINE   (France)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^d INSTITUT CURIE   (France)

^e UNIVERSITY HOSPITAL OF UDINE   (Italy)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g AMGEN LTD   (United Kingdom)

^h AMGEN INC   (United States)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; FLUOROPYRIMIDINE; OXALIPLATIN; PANITUMUMAB; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN P21;

AGE DISTRIBUTION; AGED; ARTICLE; AWARENESS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CZECH REPUBLIC; DENMARK; DRUG EFFICACY; DRUG SAFETY; EXON; FEMALE; FRANCE; GENE MUTATION; GENETIC SCREENING; GEOGRAPHIC DISTRIBUTION; GERMANY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; METASTATIC COLORECTAL CANCER; NETHERLANDS; OBSERVATIONAL STUDY; ONCOGENE K RAS; SPAIN; SWEDEN; COLORECTAL NEOPLASMS; DEMOGRAPHY; EUROPE; GENETICS; HEALTH SURVEY; MEDICAL RECORD; PHYSICIAN; SECONDARY; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; DEMOGRAPHY; EUROPE; EXONS; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MEDICAL RECORDS; PHYSICIANS; PROTO-ONCOGENE PROTEINS P21(RAS); TREATMENT OUTCOME;

EID: 84949477153     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140717     Document Type: Article

References (30)

1. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671. doi: 10.1200/JCO.2008.20.8397 PMID: 19114683
2. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345. PMID: 15269313
3. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048. PMID: 18003960
4. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, et al. (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26: 2311-2319. doi: 10.1200/JCO.2007.13.1193 PMID: 18390971
5. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417. doi: 10.1056/NEJMoa0805019 PMID: 19339720
6. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664. PMID: 17470858
7. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, et al. (2008) Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 26: 5335-5343. doi: 10.1200/JCO.2008.16.3758 PMID: 18854570
8. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634. doi: 10.1200/JCO.2007.14.7116 PMID: 18316791
9. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, et al. (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to antiepidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648. PMID: 17363584
10. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, et al. (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508-515. PMID: 17998284
11. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, et al. (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96: 1166-1169. PMID: 17375050
12. Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, et al. (2008) Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 7: 184-190. doi: 10.3816/CCC.2008.n.024 PMID: 18621636
13. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG (2009) KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 27: 1130-1136. doi: 10.1200/JCO.2008.19.8168 PMID: 19124802
14. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765. doi: 10.1056/NEJMoa0804385 PMID: 18946061
15. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379. doi: 10.1200/JCO.2007.12.5906 PMID: 18202412
16. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705. doi: 10.1200/JCO.2009.27.4860 PMID: 20921465
17. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, et al. (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28: 4706-4713. doi: 10.1200/JCO.2009.27.6055 PMID: 20921462
18. Van Cutsem E, Nordlinger B, Cervantes A (2010) Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 21 Suppl 5: v93-v97. doi: 10.1093/annonc/mdq222 PMID: 20555112
19. National Comprehensive Cancer Network (2009) Clinical practice guidelines in oncology: colon cancer. http://wwwnccnorg/professionals/physician-gls/PDF/colonpdf.
20. Ciardiello F, Tejpar S, Normanno N, Mercadante D, Teague T, et al. (2011) Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Target Oncol 6: 133-145. doi: 10.1007/s11523-011-0181-x PMID: 21630045
21. Cox SL, Zlot AI, Silvey K, Elliott D, Horn T, et al. (2012) Patterns of cancer genetic testing: a randomized survey of Oregon clinicians. J Cancer Epidemiol 2012: 294730. doi: 10.1155/2012/294730 PMID: 23150730
22. Harris JN, Liljestrand P, Alexander GL, Goddard KA, Kauffman T, et al. (2013) Oncologists' attitudes toward KRAS testing: a multisite study. Cancer Med 2: 881-888. doi: 10.1002/cam4.135 PMID: 24403261
23. Smith D, Rouyer M, Francois E, Mitry E, Monnereau A, et al. (2011) Use of cetuximab in a real-life setting in France with respect to KRAS status: Preliminary results of EREBUS cohort study. J Clin Oncol 29: Abstract e14094.
24. Webster J, Kauffman TL, Feigelson HS, Pawloski PA, Onitilo AA, et al. (2013) KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings. Cancer Epidemiol Biomarkers Prev 22: 91-101. doi: 10.1158/1055-9965.EPI-12-0545 PMID: 23155138
25. Francke AL, Smit MC, de Veer AJ, Mistiaen P (2008) Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Mak 8: 38. doi: 10.1186/1472-6947-8-38 PMID: 18789150
26. Davis KJ, Landis SH, Oh YM, Mannino DM, Han MK, et al. (2015) Continuing to Confront COPD International Physician Survey: physician knowledge and application of COPD management guidelines in 12 countries. Int J Chron Obstruct Pulmon Dis 10: 39-55. doi: 10.2147/COPD.S70162 PMID: 25565799
27. Lledo A, Dellva MA, Strombom IM, Wilkie JL, Jungemann ME, et al. (2007) Awareness of potential valvulopathy risk with pergolide and changes in clinical practice after label change: a survey among European neurologists. Eur J Neurol 14: 644-649. PMID: 17539942
28. Goldberg SL, Chen L, Guerin A, Macalalad AR, Liu N, et al. (2013) Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. Curr Med Res Opin 29: 1075-1082. doi: 10.1185/03007995.2013.812034 PMID: 23738923
29. Witjes JA, Palou J, Soloway M, Lamm D, Kamat AM, et al. (2013) Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guerin (BCG): results of an international individual patient data survey (IPDS). BJU Int 112: 742-750. doi: 10.1111/bju.12012 PMID: 23452187
30. Kellerman SE, Herold J (2001) Physician response to surveys. A review of the literature. Am J Prev Med 20: 61-67.